NASDAQ:ALRN - Aileron Therapeutics Stock Price, News, & Analysis

Aileron Therapeutics trades on the NASDAQ under the ticker symbol "ALRN."

Aileron Therapeutics Inc (NASDAQ:ALRN) released its quarterly earnings data on Wednesday, May, 8th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by $0.13. View Aileron Therapeutics' Earnings History.

Aileron Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for Aileron Therapeutics.

3 Wall Street analysts have issued 12-month price objectives for Aileron Therapeutics' shares. Their forecasts range from $5.00 to $7.00. On average, they anticipate Aileron Therapeutics' share price to reach $6.00 in the next twelve months. This suggests a possible upside of 566.7% from the stock's current price. View Analyst Price Targets for Aileron Therapeutics.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aileron Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aileron Therapeutics.

News headlines about ALRN stock have trended very negative recently, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Aileron Therapeutics earned a news sentiment score of -3.1 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Aileron Therapeutics.

Aileron Therapeutics saw a drop in short interest in May. As of May 31st, there was short interest totalling 458,200 shares, a drop of 44.9% from the April 30th total of 831,300 shares. Based on an average daily volume of 204,800 shares, the short-interest ratio is presently 2.2 days. Currently, 5.5% of the shares of the stock are short sold. View Aileron Therapeutics' Current Options Chain.

Some companies that are related to Aileron Therapeutics include IVERIC bio (ISEE), CTI BioPharma (CTIC), Moleculin Biotech (MBRX), Zafgen (ZFGN), Ophthotech (OPHT), Proteostasis Therapeutics (PTI), Sunesis Pharmaceuticals (SNSS), Zosano Pharma (ZSAN), AEterna Zentaris (AEZS), Elite Pharmaceuticals (ELTP), KemPharm (KMPH), Sierra Oncology (SRRA), IntelGenx Technologies (IGXT), Forward Pharma A/S (FWP) and DiaMedica Therapeutics (DMAC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aileron Therapeutics investors own include Portola Pharmaceuticals (PTLA), Lexicon Pharmaceuticals (LXRX), Iovance Biotherapeutics (IOVA), Aurora Cannabis (ACB), Amgen (AMGN), Home Depot (HD), Thermo Fisher Scientific (TMO), Abeona Therapeutics (ABEO), Cisco Systems (CSCO) and Alibaba Group (BABA).

(ALRN) raised $61 million in an initial public offering (IPO) on Thursday, June 29th 2017. The company issued 3,800,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Aileron Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Jennison Associates LLC (13.72%) and Brave Asset Management Inc. (0.11%). Company insiders that own Aileron Therapeutics stock include Apple Tree Partners Ii Lp, Bioventures Ltd Novartis, Cvf, Llc, Donald Dougherty, John P Phd Longenecker, Lilly Ventures Fund I Llc, Manuel Aivado and Reinhard J Ambros. View Institutional Ownership Trends for Aileron Therapeutics.

ALRN stock was sold by a variety of institutional investors in the last quarter, including Brave Asset Management Inc.. Company insiders that have sold Aileron Therapeutics company stock in the last year include Apple Tree Partners Ii Lp and Bioventures Ltd Novartis. View Insider Buying and Selling for Aileron Therapeutics.

ALRN stock was acquired by a variety of institutional investors in the last quarter, including Jennison Associates LLC. Company insiders that have bought Aileron Therapeutics stock in the last two years include Cvf, Llc, Donald Dougherty, John P Phd Longenecker, Lilly Ventures Fund I Llc, Manuel Aivado and Reinhard J Ambros. View Insider Buying and Selling for Aileron Therapeutics.

Shares of ALRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ALRN stock can currently be purchased for approximately $0.90.

Aileron Therapeutics has a market capitalization of $13.39 million. Aileron Therapeutics employs 23 workers across the globe.View Additional Information About Aileron Therapeutics.

The official website for Aileron Therapeutics is http://www.aileronrx.com/.

Aileron Therapeutics' mailing address is 490 Arsenal Way, Watertown MA, 02472. The company can be reached via phone at 617-995-0900 or via email at [email protected]